Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA6 | P23280 | 5/20 | 0.57 |
| ▸ | CA7 | P43166 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 4/20 | 0.57 |
| ▸ | CA4 | P22748 | 4/20 | 0.57 |
| ▸ | CA5A | P35218 | 4/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | CASP2 | P42575 | 2/20 | 0.57 |
| ▸ | F13A1 | P00488 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | THPO | P40225 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18158019 | 0.98 | CA12 (0.55) | CA12CA6CA7CA9CA14 | |
| Hydrochloric Acid SCHEMBL11553303 | 0.98 | UBE2N (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL12335786 | 0.93 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21799750 | 0.91 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21799439 | 0.91 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21799994 | 0.91 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21799567 | 0.91 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21799730 | 0.91 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL21799615 | 0.91 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| SCHEMBL18232511 | 0.91 | CA12 (0.56) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623398-B1 | RESIN COMPOSITION COMPRISING A MODIFIED BLOCK COPOLYMER AND METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER | ASAHI CHEMICAL IND (JP) | 2024-08-28 | — | — | EP | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230002790-A1 | POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| CN-110603273-B | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-20220154219-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | THE JOHNS HOPKINS UNIVERSITY | 2022-05-19 | — | — | US | disclosed |
| US-11124593-B2 | Modified block copolymer, method for producing modified block copolymer, and resin composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-21 | — | — | US | disclosed |
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | THE JOHNS HOPKINS UNIVERSITY | 2020-10-22 | — | — | US | disclosed |
| US-20200199282-A1 | Modified Block Copolymer, Method for Producing Modified Block Copolymer, and Resin Composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| EP-3623398-A1 | MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION | Asahi Kasei Kabushiki Kaisha (JP) | 2020-03-18 | — | — | EP | disclosed |
| CN-110603273-A | Modified block copolymer, method for producing modified block copolymer, and resin composition | 旭化成株式会社 | 2019-12-20 | — | — | CN | disclosed |
| EP-3293195-A1 | COMPOUNDS FOR USE IN TREATING DIABETES | OHR Pharmaceutical, Inc. (US) | 2018-03-14 | — | — | EP | disclosed |
| CN-107074734-A | Process for making N-alkyl polyamines | 库扎环球有限责任公司 | 2017-08-18 | — | — | CN | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-7371733-B2 | Anti bacterial compounds | UTAH STATE UNIVERSITY (US) | 2008-05-13 | — | — | US | disclosed |
| WO-2003101382-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF ANTHRAX AND INHIBITING LETHAL FACTOR | MERCK & CO., INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330396-A1 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | MYOC, MTREX, SLC26A4 | CA12 704/4885CA6 422/4885CA7 1440/4885 |
| US-20220154219-A1 | GENE DELIVERY PARTICLES TO INDUCE TUMOR-DERIVED ANTIGEN PRESENTING CELLS | PBK, MICA, STAT3 | CA12 3289/4885CA6 3564/4885CA7 4222/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | CA12 1062/4885CA6 1100/4885CA7 1694/4885 |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | POLRMT, HDGF, PCNP | CA12 1062/4885CA6 1100/4885CA7 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.